MedTrace Logo

UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study

NCT07163624 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 211

Last updated 2026-05-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of UBT251 injection after 24 weeks of continuous administration in patients with type 2 diabetes mellitus and to recommend the dosing regimen for the Phase III clinical trial.

Conditions

  • Type 2 Diabetes Mellitus (T2DM)

Interventions

DRUG

UBT251 Injection 2.0 mg and UBT251 Injection Placebo

UBT251 Injection and UBT251 Injection Placebo once weekly

DRUG

UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo

UBT251 Injection and UBT251 Injection Placebo once weekly

DRUG

UBT251 Injection 4.0 mg (ID 1.0 mg) and UBT251 Injection Placebo

UBT251 Injection and UBT251 Injection Placebo once weekly

DRUG

UBT251 Injection 6.0 mg and UBT251 Injection Placebo

UBT251 Injection and UBT251 Injection Placebo once weekly

DRUG

Semaglutide Injection (Ozempic®)

Semaglutide Injection (Ozempic®) once weekly

Sponsors & Collaborators

  • The United Bio-Technology (Hengqin) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-22
Primary Completion
2025-11-21
Completion
2025-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07163624 on ClinicalTrials.gov